Investigating the relationship between antiviral clinical effectiveness and in vitro sensitivity
Aeron’s group has established a detailed and sensitive ferret influenza infection/antiviral treatment model that monitors virological, immunological and behavioural components to assess antiviral effectiveness pre or post influenza viral infection. Using the model they can help establish an important understanding of clinical effectiveness against viruses with reduced antiviral sensitivity.
Associate Professor Aeron Hurt
(03) 9342 9314 | [email protected]
- Head Virologist
- Public Health
- Victorian Infectious Diseases Reference Laboratory (VIDRL), WHO Collaborating Centre for Reference and Research on Influenza
- Lab Group(s):
- Hurt Group
Associate Professor Aeron Hurt is the Deputy Director (Acting) of the WHO Collaborating Centre for Reference and Research on Influenza and heads the Antiviral Susceptibility Analysis Surveillance Unit and Research group. Aeron is a world leader in influenza antiviral research and regularly acts as an external Temporary Advisor to the WHO. He has completed a number of short-term consultancies for the Vietnamese Ministry of Health, the WHO, and the Australian Government related to influenza surveillance, epidemiology and laboratory analysis. Aeron is on the Editorial board of the journals Antiviral Research, Virology Journal and Infection, Ecology and Epidemiology. Aeron completed a PhD in influenza virology at Monash University and holds an honorary Principal Fellow appointment with the University of Melbourne.